Abstract:Influenza virus causes influenza, an infectious disease. The symptoms can range from mild to severe. Severe influenza infections have historically led to 250,000 to 500,000 deaths per year. Influenza viruses can be broadly classified into four types as A, B, C, and D. They are structurally similar, and place high demands on drugs. The heterotrimeric polymerase complex of the influenza virus represents a promising target for the design and improvement of novel lead compounds. Inhibition of its assembly could be proven to have an antiviral efficacy for both in vitro and in vivo activity. However, in vivo, potent lead compounds tackling this target have not been identified yet. In this study, we have used the information about two previously discovered molecules (referred to as ANA 1 and PAC-3), which revealed significant in vitro effects, and we have proposed new compounds using a computational protocol. Structural, chemical similarity calculations against the ZINC database were carried out using the Generic Match Algorithm (GMA). Putative inhibitor binding sites of the influenza virus polymerase were investigated based on the blind docking approach employing AutoDock Vina and Lead Finder. Furthermore, ligand-based virtual screenings were executed, calculating shape similarity using a Weighted Gaussian Algorithm (WEGA) and pharmacophoric properties by LigandScout. A handful of molecules were finally selected as promising inhibitors. The binding efficiency and the toxicity properties of the identified lead compound DB07972 (MolPort-002-025-261) were compared against the available drug of choice Baloxavir marboxil. The molecular dynamics simulations along with the MMPBSA calculations have shown that the novel lead compound DB07972 is capable of exhibiting better interaction and compactness. More interestingly, the novel lead compound was found to be less toxic than the control drug. The molecule was further evaluated using in vitro approaches. From the experimental analysis, the chosen compound, DB07972, showed maximal inhibition around 75% with 20 μM and was non-toxic to 100% healthy cells at the same concentration.

3'‐Dehydroxypurpurogallin‐4‐carboxamides as Influenza A Endonuclease Inhibitors: Synthesis, SAR Analysis, and Structural Characterization of Protein Complex

Synthesis and Biological Evaluation of 2‐oxo‐pyrazine‐3‐carboxamide‐yl Nucleoside Analogues and Their Epimers As Inhibitors of Influenza A Viruses

Design and Synthesis of 7-Membered Lactam Fused Hydroxypyridinones As Potent Metal Binding Pharmacophores (mbps) for Inhibiting Influenza Virus PAN Endonuclease

Nucleoside Monophosphate Complex Structures of the Endonuclease Domain from the Influenza Virus Polymerase PA Subunit Reveal the Substrate Binding Site Inside the Catalytic Center

Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors

Magnesium-Dependent Rna Binding to the Pa Endonuclease Domain of the Avian Influenza Polymerase

Identification of a Small-Molecule Inhibitor of Influenza Virus Via Disrupting the Subunits Interaction of the Viral Polymerase.

Design, synthesis, and biological activity of a novel series of 2-ureidonicotinamide derivatives against influenza A virus

Identification of Influenza PAN Endonuclease Inhibitors via 3D-QSAR Modeling and Docking-Based Virtual Screening

An integrated ligand-based modelling approach to explore the structure-property relationships of influenza endonuclease inhibitors

Design, synthesis, and preliminary evaluation of new pyrrolidine derivatives as neuraminidase inhibitors.

Identification of the Imidazo[1,2- a]pyrazine Derivative A4 as a Potential Influenza Virus Nucleoprotein Inhibitor

Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors

Structure-based methoxyflavone derivatives with potent inhibitory activity against various influenza neuraminidases

Design, synthesis, bioactivity, and DFT calculation of 2-thiazolyl-hydrazone derivatives as influenza neuraminidase inhibitors

Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors.

Indole-core inhibitors of influenza a neuraminidase: iterative medicinal chemistry and molecular modeling

Design, Synthesis and in Vitro Anti-Influenza A Virus Evaluation of Novel Quinazoline Derivatives Containing S-acetamide and NH-acetamide Moieties at C-4

Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants

Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA–PB1 Subunits Interaction

Prediction and characterization of influenza virus polymerase inhibitors through blind docking and ligand based virtual screening